Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parkinson Study Group
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parkinson Study Group,
NEUROLOGY 2004;62:330-332
© 2004 American Academy of Neurology
Brief Communications

The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD

Parkinson Study Group*

Address correspondence and reprint requests to Dr. S.R. Schwid, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave., Box 605, Rochester, NY 14642; e-mail: steven_schwid{at}urmc.rochester.edu

CEP-1347 is an inhibitor of members of the mixed lineage kinase family, key signals triggering apoptotic neuronal death. The authors performed a randomized, blinded, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and acute symptomatic effects of CEP-1347 in 30 patients with Parkinson’s disease (PD). In this short-term study, CEP-1347 was safe and well tolerated. It had no acute effect on parkinsonian symptoms or levodopa pharmacokinetics, making it well suited for larger and longer studies of its potential to modify the course of PD.

Received May 28, 2003. Accepted in final form October 10, 2003.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the January 27 issue to find the title link for this article.

*See the Appendix on page 332 for a list of contributing members.




This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
T. Thalhamer, M. A. McGrath, and M. M. Harnett
MAPKs and their relevance to arthritis and inflammation
Rheumatology, April 1, 2008; 47(4): 409 - 414.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Mishra, M. K. Barthwal, G. Sondarva, B. Rana, L. Wong, M. Chatterjee, J. R. Woodgett, and A. Rana
Glycogen Synthase Kinase-3beta Induces Neuronal Cell Death via Direct Phosphorylation of Mixed Lineage Kinase 3
J. Biol. Chem., October 19, 2007; 282(42): 30393 - 30405.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
The Parkinson Study Group PRECEPT Investigators
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
Neurology, October 9, 2007; 69(15): 1480 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. Y. Ma, R. S. Flanc, G. H. Tesch, Y. Han, R. C. Atkins, B. L. Bennett, G. C. Friedman, J.-H. Fan, and D. J. Nikolic-Paterson
A Pathogenic Role for c-Jun Amino-Terminal Kinase Signaling in Renal Fibrosis and Tubular Cell Apoptosis
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 472 - 484.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. B. West, D. J. Moore, C. Choi, S. A. Andrabi, X. Li, D. Dikeman, S. Biskup, Z. Zhang, K.-L. Lim, V. L. Dawson, et al.
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity
Hum. Mol. Genet., January 15, 2007; 16(2): 223 - 232.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Sui, S. Fan, L. Sniderhan, E. Reisinger, A. Litzburg, G. Schifitto, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar
Inhibition of Mixed Lineage Kinase 3 Prevents HIV-1 Tat-Mediated Neurotoxicity and Monocyte Activation
J. Immunol., July 1, 2006; 177(1): 702 - 711.
[Abstract] [Full Text] [PDF]